Gregg Eure, MD

Articles by Gregg Eure, MD

Making Sense of the Reintervention Rate for BPH

ByGregg Eure, MD,LAURENCE A. LEVINE, MD

March 7th 2021

Letter: BPH guidelines may ignore FDA, insurance criteria

ByGregg Eure, MD

May 12th 2020

"As we seek to understand MIST retreatment rates, as Houlihan and Köhler suggest, we must rely upon real-world population data," writes Gregg Eure, MD, in a letter to the editor.

Latest Updated Articles

Making Sense of the Reintervention Rate for BPH
March 7th 2021
Letter: BPH guidelines may ignore FDA, insurance criteria
May 12th 2020

Gregg Eure, MD

Articles by Gregg Eure, MD

Making Sense of the Reintervention Rate for BPH

Letter: BPH guidelines may ignore FDA, insurance criteria

Latest Updated Articles

Trending on Urology Times

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer